Evidence map›Paper›PMID 23434930›Full record

ArticleDiabetes2013

Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model.

Ken T Coppieters, Natalie Amirian, Philippe P Pagni, Carmen Baca Jones, Anna Wiberg, Stanley Lasch, Edith Hintermann, Urs Christen, Matthias G von Herrath

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Immune cell trafficking to the islets during type 1 diabetes.Clinical and experimental immunology · 2019
    Review
  6. Article
  7. Article
  8. CD11cFrontiers in immunology · 2019
    Article
  9. Review
  10. Pancreatic islet inflammation: an emerging role for chemokines.Journal of molecular endocrinology · 2017
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Ken T CoppietersType 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Natalie Amirian
Philippe P Pagni
Carmen Baca Jones
Anna Wiberg
Stanley Lasch
Edith Hintermann
Urs Christen
Matthias G von Herrath
La Jolla Institute for Immunology · USGoethe University Frankfurt · DENovo Nordisk (United States) · USUniversity Hospital Frankfurt · DE

Funding

CXCR3 Chemokines in Type I DiabetesR01DK066346 · NIDDK · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI VON HERRATH, MATTHIAS G. · 2004 to 2009
$1.5M
NIDDK NIH HHS R01 DK066346NIDDK NIH HHS R01-DK-66346-05
6 · The paper itself

Abstract

Cytotoxic T lymphocytes (CTLs) constitute a major effector population in pancreatic islets from patients suffering from type 1 diabetes (T1D) and thus represent attractive targets for intervention. Some studies have suggested that blocking the interaction between the chemokine CXCL10 and its receptor CXCR3 on activated CTLs potently inhibits their recruitment and prevents β-cell death. Since recent studies on human pancreata from T1D patients have indicated that both ligand and receptor are abundantly present, we reevaluated whether their interaction constitutes a pivotal node within the chemokine network associated with T1D. Our present data in a viral mouse model challenge the notion that specific blockade of the CXCL10/CXCR3 chemokine axis halts T1D onset and progression.

Indexed as

AnimalsAntibodies, NeutralizingChemokine CXCL10Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Islets of LangerhansMiceReceptors, CXCR3Signal TransductionT-Lymphocytes, CytotoxicAntibodies, NeutralizingChemokine CXCL10Cxcl10 protein, mouseCxcr3 protein, mouseReceptors, CXCR3

Identifiers

PMID23434930
PMCPMC3712024
OpenAlexW2169510681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.